{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T12:11:04Z","timestamp":1785845464932,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T00:00:00Z","timestamp":1562889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T00:00:00Z","timestamp":1562889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19fk0210025h0003"],"award-info":[{"award-number":["JP19fk0210025h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The assessment of liver fibrosis is essential because it correlates with mortality risk in nonalcoholic fatty liver disease (NAFLD). This study aims to examine whether serum fibrosis markers could identify candidate patients likely to have advanced fibrosis. We enrolled 352 patients with NAFLD and performed liver biopsies in 97 patients. The area under the receiver operating characteristic curve (AUROC) of liver stiffness by magnetic resonance elastography for histological advanced fibrosis was 0.910, and the optimal cutoff value was 4.07\u2009kPa. To predict severe liver stiffness (\u22654.07\u2009kPa), the AUROC for <jats:italic>Wisteria floribunda<\/jats:italic> agglutinin-positive mac-2 binding protein (WFA<jats:sup>+<\/jats:sup>-M2BP) and FIB-4 were 0.897 (cutoff value, 1.08) and 0.880 (cutoff value, 2.53), respectively. After stratification of patients into four age groups as quartile, the optimal cutoff values of WFA<jats:sup>+<\/jats:sup>-M2BP for predicting severe liver stiffness were similar in each group (1.09, 1.08, 1.10, and 1.12). On the other hand, those of FIB-4 increased in parallel with age (1.47, 2.19, 2.99, and 3.88). In conclusion, WFA<jats:sup>+<\/jats:sup>-M2BP was precise for estimating severe liver stiffness in NAFLD with single cutoff value independent of age. Hence, identifying high-risk cases using WFA<jats:sup>+<\/jats:sup>-M2BP from a large number of NAFLD patients is clinically significant.<\/jats:p>","DOI":"10.1038\/s41598-019-46172-1","type":"journal-article","created":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T10:03:41Z","timestamp":1562925821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease"],"prefix":"10.1038","volume":"9","author":[{"given":"Nobuharu","family":"Tamaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakura","family":"Kirino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiya","family":"Watakabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Takaura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Itakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namiki","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,12]]},"reference":[{"key":"46172_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73\u201384 (2016).","journal-title":"Hepatology"},{"key":"46172_CR2","first-page":"13282","volume":"27","author":"K Tanaka","year":"2018","unstructured":"Tanaka, K. et al. Epidemiological survey of hemoglobin A1c and liver fibrosis in a general population with non-alcoholic fatty liver disease. Hepatol Res 27, 13282 (2018).","journal-title":"Hepatol Res"},{"key":"46172_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo, P. et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 149, 389\u2013397 e310 (2015).","journal-title":"Gastroenterology"},{"key":"46172_CR4","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai, P. S. et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology 65, 1557\u20131565 (2017).","journal-title":"Hepatology"},{"key":"46172_CR5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","volume":"155","author":"E Vilar-Gomez","year":"2018","unstructured":"Vilar-Gomez, E. et al. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. Gastroenterology 155, 443\u2013457 e417 (2018).","journal-title":"Gastroenterology"},{"key":"46172_CR6","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMra011775","volume":"346","author":"P Angulo","year":"2002","unstructured":"Angulo, P. Nonalcoholic fatty liver disease. N Engl J Med 346, 1221\u20131231 (2002).","journal-title":"N Engl J Med"},{"key":"46172_CR7","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/hep.22742","volume":"49","author":"DC Rockey","year":"2009","unstructured":"Rockey, D. C., Caldwell, S. H., Goodman, Z. D., Nelson, R. C. & Smith, A. D. Liver biopsy. Hepatology 49, 1017\u20131044 (2009).","journal-title":"Hepatology"},{"key":"46172_CR8","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.cgh.2007.06.012","volume":"5","author":"M Yin","year":"2007","unstructured":"Yin, M. et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 5, 1207\u20131213 e1202 (2007).","journal-title":"Clin Gastroenterol Hepatol"},{"key":"46172_CR9","first-page":"31323","volume":"28","author":"M Higuchi","year":"2018","unstructured":"Higuchi, M. et al. Prediction of hepatocellular carcinoma after sustained virological responses using magnetic resonance elastography. Clin Gastroenterol Hepatol 28, 31323\u201331325 (2018).","journal-title":"Clin Gastroenterol Hepatol"},{"key":"46172_CR10","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","volume":"150","author":"K Imajo","year":"2016","unstructured":"Imajo, K. et al. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. Gastroenterology 150, 626\u2013637 e627 (2016).","journal-title":"Gastroenterology"},{"key":"46172_CR11","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","volume":"152","author":"CC Park","year":"2017","unstructured":"Park, C. C. et al. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease. Gastroenterology 152, 598\u2013607 e592 (2017).","journal-title":"Gastroenterology"},{"key":"46172_CR12","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/hep.27647","volume":"61","author":"R Loomba","year":"2015","unstructured":"Loomba, R. et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 61, 1239\u20131250 (2015).","journal-title":"Hepatology"},{"key":"46172_CR13","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","volume":"391","author":"SA Harrison","year":"2018","unstructured":"Harrison, S. A. et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 391, 1174\u20131185 (2018).","journal-title":"Lancet"},{"key":"46172_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00535-017-1414-2","volume":"53","author":"M Yoneda","year":"2018","unstructured":"Yoneda, M. et al. Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. J Gastroenterol 53, 181\u2013196 (2018).","journal-title":"J Gastroenterol"},{"key":"46172_CR15","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jhep.2017.11.028","volume":"68","author":"R Loomba","year":"2018","unstructured":"Loomba, R. Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions. J Hepatol 68, 296\u2013304 (2018).","journal-title":"J Hepatol"},{"key":"46172_CR16","doi-asserted-by":"publisher","first-page":"e15167","DOI":"10.5812\/hepatmon.15167","volume":"14","author":"O Pournik","year":"2014","unstructured":"Pournik, O. et al. Inter-observer and Intra-observer Agreement in Pathological Evaluation of Non-alcoholic Fatty Liver Disease Suspected Liver Biopsies. Hepat Mon 14, e15167 (2014).","journal-title":"Hepat Mon"},{"key":"46172_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/srep01065","volume":"3","author":"A Kuno","year":"2013","unstructured":"Kuno, A. et al. A serum \u201csweet-doughnut\u201d protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep 3, 1065 (2013).","journal-title":"Sci Rep"},{"key":"46172_CR18","doi-asserted-by":"publisher","first-page":"E82","DOI":"10.1111\/hepr.12466","volume":"45","author":"N Tamaki","year":"2015","unstructured":"Tamaki, N. et al. Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. Hepatol Res 45, E82\u201388 (2015).","journal-title":"Hepatol Res"},{"key":"46172_CR19","first-page":"13233","volume":"20","author":"Y Yasui","year":"2018","unstructured":"Yasui, Y. et al. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus. Hepatol Res 20, 13233 (2018).","journal-title":"Hepatol Res"},{"key":"46172_CR20","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s00535-014-1007-2","volume":"50","author":"M Abe","year":"2015","unstructured":"Abe, M. et al. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 50, 776\u2013784 (2015).","journal-title":"J Gastroenterol"},{"key":"46172_CR21","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/hepr.13046","volume":"48","author":"M Atsukawa","year":"2018","unstructured":"Atsukawa, M. et al. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein more reliably distinguishes liver fibrosis stages in non-alcoholic fatty liver disease than serum Mac-2 binding protein. Hepatol Res 48, 424\u2013432 (2018).","journal-title":"Hepatol Res"},{"key":"46172_CR22","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/hepr.13054","volume":"48","author":"M Kawanaka","year":"2018","unstructured":"Kawanaka, M. et al. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. Hepatol Res 48, 521\u2013528 (2018).","journal-title":"Hepatol Res"},{"key":"46172_CR23","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1111\/jgh.14156","volume":"33","author":"Y Ogawa","year":"2018","unstructured":"Ogawa, Y. et al. Wisteria floribunda agglutinin-positive Mac-2-binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 33, 1795\u20131803 (2018).","journal-title":"J Gastroenterol Hepatol"},{"key":"46172_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1365-2893.2012.01635.x","volume":"20","author":"N Tamaki","year":"2013","unstructured":"Tamaki, N. et al. Noninvasive estimation of fibrosis progression overtime using the FIB-4 index in chronic hepatitis C. J Viral Hepat 20, 72\u201376 (2013).","journal-title":"J Viral Hepat"},{"key":"46172_CR25","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s00535-013-0914-y","volume":"49","author":"N Tamaki","year":"2014","unstructured":"Tamaki, N. et al. Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients. J Gastroenterol 49, 1495\u20131503 (2014).","journal-title":"J Gastroenterol"},{"key":"46172_CR26","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/hepr.12405","volume":"45","author":"Y Takahashi","year":"2015","unstructured":"Takahashi, Y. et al. Non-alcoholic fatty liver disease fibrosis score and FIB-4 scoring system could identify patients at risk of systemic complications. Hepatol Res 45, 667\u2013675 (2015).","journal-title":"Hepatol Res"},{"key":"46172_CR27","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1007\/s00535-018-1474-y","volume":"53","author":"H Ishiba","year":"2018","unstructured":"Ishiba, H. et al. The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. J Gastroenterol 53, 1216\u20131224 (2018).","journal-title":"J Gastroenterol"},{"key":"46172_CR28","doi-asserted-by":"crossref","unstructured":"Kurosaki, M. & Izumi, N. External validation of FIB-4: diagnostic accuracy is limited in elderly populations. Hepatology 47, 352; author reply 352\u2013353 (2008).","DOI":"10.1002\/hep.21978"},{"key":"46172_CR29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/jgh.14448","volume":"34","author":"T Ito","year":"2019","unstructured":"Ito, T. et al. Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients. J Gastroenterol Hepatol 34, 207\u2013214 (2019).","journal-title":"J Gastroenterol Hepatol"},{"key":"46172_CR30","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 43, 1317\u20131325 (2006).","journal-title":"Hepatology"},{"key":"46172_CR31","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo, P. et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45, 846\u2013854 (2007).","journal-title":"Hepatology"},{"key":"46172_CR32","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/gut.2007.146019","volume":"57","author":"SA Harrison","year":"2008","unstructured":"Harrison, S. A., Oliver, D., Arnold, H. L., Gogia, S. & Neuschwander-Tetri, B. A. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 57, 1441\u20131447 (2008).","journal-title":"Gut"},{"key":"46172_CR33","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","volume":"38","author":"CT Wai","year":"2003","unstructured":"Wai, C. T. et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38, 518\u2013526 (2003).","journal-title":"Hepatology"},{"key":"46172_CR34","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313\u20131321 (2005).","journal-title":"Hepatology"},{"key":"46172_CR35","doi-asserted-by":"crossref","unstructured":"Pathological Findings of NASH and NAFLD: for Guidebook of NASH and NAFLD, 2015: The Japan Society of Hepatology. Hepatol Res 47, 3\u201310 (2017).","DOI":"10.1111\/hepr.12847"},{"key":"46172_CR36","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48, 452\u2013458 (2013).","journal-title":"Bone Marrow Transplant"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46172-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46172-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46172-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T11:25:17Z","timestamp":1671276317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46172-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,12]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["46172"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-46172-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,12]]},"assertion":[{"value":"1 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10109"}}